Screening for GPCR Ligands Using Surface Plasmon Resonance

G-protein coupled receptors (GPCRs) are a class of drug targets of primary importance. However, receptor assays are based on measurement of either ligand displacement or downstream functional responses, rather than direct observation of ligand binding. Issues of allosteric modulation, probe dependence, and functional selectivity create challenges in selecting suitable assays formats. Therefore, a method that directly measures GPCR–ligand interactions, independent of binding site, probe, and signaling pathway would be a useful primary and orthogonal screening method. We have developed a GPCR biosensor assay protocol that offers the opportunity for high-throughput label-free screening that directly measures GPCR–ligand interactions. The biosensor-based direct screening method identifies the interaction of both orthosteric and allosteric ligands with solubilized, native GPCRs, in a label-free and cell-free environment, thus overcoming the limitations of indirect and displacement assay methods. We exemplify the method by the discovery of novel ligands for the chemokine receptor, CCR5, that are ligand efficient fragments.

[1]  J. Errey,et al.  Biacore analysis with stabilized G-protein-coupled receptors. , 2011, Analytical biochemistry.

[2]  Terry Kenakin,et al.  Allosteric Theory: Taking Therapeutic Advantage of the Malleable Nature of GPCRs , 2007, Current neuropharmacology.

[3]  Meir Glick,et al.  Enrichment of High-Throughput Screening Data with Increasing Levels of Noise Using Support Vector Machines, Recursive Partitioning, and Laplacian-Modified Naive Bayesian Classifiers , 2006, J. Chem. Inf. Model..

[4]  Anthony E. Klon,et al.  Finding more needles in the haystack: A simple and efficient method for improving high-throughput docking results. , 2004, Journal of medicinal chemistry.

[5]  T. Williams,et al.  Small Molecule Receptor Agonists and Antagonists of CCR3 Provide Insight into Mechanisms of Chemokine Receptor Activation* , 2007, Journal of Biological Chemistry.

[6]  Xiaoyang Xia,et al.  Classification of kinase inhibitors using a Bayesian model. , 2004, Journal of medicinal chemistry.

[7]  Andreas Bender,et al.  Bayesian methods in virtual screening and chemical biology. , 2011, Methods in molecular biology.

[8]  G. V. Paolini,et al.  Global mapping of pharmacological space , 2006, Nature Biotechnology.

[9]  Nathan Robertson,et al.  The properties of thermostabilised G protein-coupled receptors (StaRs) and their use in drug discovery , 2011, Neuropharmacology.

[10]  T. Kenakin,et al.  The CCR5 Receptor-Based Mechanism of Action of 873140, a Potent Allosteric Noncompetitive HIV Entry Inhibitor , 2005, Molecular Pharmacology.

[11]  T. Kenakin,et al.  The Relative Activity of “Function Sparing” HIV-1 Entry Inhibitors on Viral Entry and CCR5 Internalization: Is Allosteric Functional Selectivity a Valuable Therapeutic Property? , 2009, Molecular Pharmacology.

[12]  David G Myszka,et al.  A biosensor-based approach toward purification and crystallization of G protein-coupled receptors. , 2006, Analytical biochemistry.

[13]  David G Myszka,et al.  Solubilization, stabilization, and purification of chemokine receptors using biosensor technology. , 2005, Analytical biochemistry.

[14]  David A. Price,et al.  Maraviroc (UK-427,857), a Potent, Orally Bioavailable, and Selective Small-Molecule Inhibitor of Chemokine Receptor CCR5 with Broad-Spectrum Anti-Human Immunodeficiency Virus Type 1 Activity , 2005, Antimicrobial Agents and Chemotherapy.

[15]  Jun Zhang,et al.  Molecular Interactions of CCR5 with Major Classes of Small-Molecule Anti-HIV CCR5 Antagonists , 2008, Molecular Pharmacology.

[16]  Jun Zhang,et al.  Molecular Interactions of CCR5 with Major Classes of Small-Molecule Anti-HIV CCR5 Antagonists , 2008, Molecular Pharmacology.

[17]  Ravinder Abrol,et al.  Predictions of CCR1 Chemokine Receptor Structure and BX 471 Antagonist Binding Followed by Experimental Validation* , 2006, Journal of Biological Chemistry.

[18]  William L. Jorgensen,et al.  Journal of Chemical Information and Modeling , 2005, J. Chem. Inf. Model..

[19]  Meir Glick,et al.  Prediction of Biological Targets for Compounds Using Multiple-Category Bayesian Models Trained on Chemogenomics Databases , 2006, J. Chem. Inf. Model..

[20]  P. Willett,et al.  Comparison of topological descriptors for similarity-based virtual screening using multiple bioactive reference structures. , 2004, Organic & biomolecular chemistry.

[21]  D. Nicholls,et al.  Identification of a Putative Intracellular Allosteric Antagonist Binding-Site in the CXC Chemokine Receptors 1 and 2 , 2008, Molecular Pharmacology.

[22]  S. Rees,et al.  Protean Agonism at the Dopamine D2 Receptor: (S)-3-(3-Hydroxyphenyl)-N-propylpiperidine Is an Agonist for Activation of Go1 but an Antagonist/Inverse Agonist for Gi1,Gi2, and Gi3 , 2007, Molecular Pharmacology.

[23]  M. Bouvier,et al.  The evasive nature of drug efficacy: implications for drug discovery. , 2007, Trends in pharmacological sciences.

[24]  David Rogers,et al.  Extended-Connectivity Fingerprints , 2010, J. Chem. Inf. Model..

[25]  P. Sexton,et al.  Allosteric modulation of G protein-coupled receptors: A pharmacological perspective , 2011, Neuropharmacology.

[26]  David G Myszka,et al.  Analyzing ligand and small molecule binding activity of solubilized GPCRs using biosensor technology. , 2006, Analytical biochemistry.

[27]  Kazuki Ohno,et al.  Two 'Golden Ratio' indices in fragment-based drug discovery. , 2009, Drug discovery today.

[28]  M. Fidock,et al.  Allosteric effects of antagonists on signalling by the chemokine receptor CCR5. , 2007, Biochemical pharmacology.

[29]  I. Navratilova,et al.  CCR5 pharmacology methodologies and associated applications. , 2009, Methods in enzymology.

[30]  Arthur Christopoulos,et al.  Functional Selectivity and Classical Concepts of Quantitative Pharmacology , 2007, Journal of Pharmacology and Experimental Therapeutics.

[31]  K. Wreggett,et al.  An Intracellular Allosteric Site for a Specific Class of Antagonists of the CC Chemokine G Protein-Coupled Receptors CCR4 and CCR5 , 2008, Molecular Pharmacology.